AC
MTNB icon

AWH Capital’s Matinas BioPharma MTNB Stock Holding History

AWH Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,500
Closed -$136K – 28
2021
Q2 		$136K Hold
3,500
– – 0.12% 28
2021
Q1 		$184K Buy
+3,500
New +$235K 0.18% 29

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AWH Capital's MTNB Position: Q3 2021 in Review

AWH Capital sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 3,500 shares — an estimated $136K sold.

AWH Capital first reported a position in MTNB in Q1 2021 and held it in 2 quarters. The position peaked at $184K in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

  • AWH Capital reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
  • AWH Capital sold 3,500 Matinas BioPharma shares in Q3 2021, an estimated $136K.
  • AWH Capital first reported a position in Matinas BioPharma in Q1 2021 and held it in 2 quarters.
  • AWH Capital's Matinas BioPharma position peaked at $184K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on AWH Capital's 13F filing for Q3 2021, filed 15 Nov 2021.